Are there allergens, fillers, or contaminants reported in Rosabella Moringa products in 2025?
Executive summary
There are documented reports in 2025 of Salmonella contamination in multiple packaged moringa leaf powder products that prompted nationwide recalls, but the available public sources reviewed do not mention Rosabella by name; therefore no direct evidence from these sources shows allergens, fillers, or contaminants specifically in Rosabella-branded moringa products (limitation noted) [1] [2] [3]. Federal investigations traced illnesses to a single supplier lot of moringa leaf powder imported from India, and the recalls and outbreak information focus on microbial contamination (Salmonella), not on undeclared allergens or non-nutritive fillers [4] [5].
1. Salmonella—confirmed contaminant driving 2025 recalls
Federal agencies linked a multistate Salmonella Richmond outbreak to products made with a single lot of organic moringa leaf powder supplied by Vallon Farmdirect PVT LTD of Jodhpur, India, and public notices and recalls from the FDA and CDC confirm that the contamination was microbial—Salmonella—rather than a chemical contaminant or filler [4] [3] [5].
2. Which brands and lots were implicated—and how widespread were distributions
The recalls named specific brands and distributors: Member’s Mark Super Greens dietary supplement powders, Food To Live’s Organic Moringa Leaf Powder and Organic Supergreens, and Africa Imports’ Organic Moringa Leaf Powder (with lot-based scope), and agencies warned that affected products had been sold through major retailers and third‑party e‑commerce platforms including Amazon, Walmart, Target, Etsy and eBay [6] [1] [2] [7].
3. Human impact reported in official updates
CDC and FDA reporting tied the contaminated lot to 11 confirmed illnesses across seven states with three hospitalizations during the outbreak period; these epidemiologic and laboratory data supported the public-health recalls and advisories to stop using and to dispose of or return affected products [3] [5] [8].
4. No reporting in these sources of allergens or “fillers” in moringa products
The publicly available outbreak summaries, recall notices, and news coverage in this dataset uniformly describe Salmonella contamination as the hazard prompting recalls; none of the cited FDA, CDC, state health, or news items in this collection report undeclared allergens, adulterating fillers, or non‑microbial contaminants in the implicated moringa batches [1] [2] [3] [9]. That absence in the reporting does not prove such problems do not exist elsewhere, only that they were not identified or alleged in these specific investigations and notices.
5. Limitations, alternative viewpoints, and what remains unknown
Public records here are clear that a specific supplier lot tested positive for Salmonella and that several brands sourced from that lot were recalled [1] [4], but the dataset includes no reference to Rosabella products—so it is not possible from these sources to confirm or deny contamination, allergens, or fillers in Rosabella-branded moringa in 2025; independent testing, company disclosures, or additional regulatory records would be required to answer that narrower brand question (limitation). Consumer-safety reporting emphasizes microbial risk for the affected lots and urges cleaning of surfaces and disposal of recalled product [3] [1], while outlets covering the story highlighted supply-chain links to a single imported lot as the implicit weak point [5] [7].
6. Practical takeaway from the documented 2025 events
Regulatory action in 2025 focused on removing Salmonella‑contaminated moringa leaf powder from the market and notifying consumers and retailers about specific lot numbers and brands; anyone with suspected affected product was advised to stop using it and follow recall instructions [1] [2] [3]. For any brand not named in these recalls—including Rosabella—the public record in this dataset contains no reports of allergens, fillers, or contaminants; a definitive statement about Rosabella would require targeted recall lists, company statements, or laboratory findings not present here (limitation).